Welcome to our dedicated page for Moleculin Biotec SEC filings (Ticker: MBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Moleculin Biotech, Inc. (Nasdaq: MBRX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central to understanding Moleculin’s progress as a Phase 3 clinical stage pharmaceutical company focused on hard-to-treat tumors and certain viral infections.
Through Moleculin’s Form 8-K current reports, investors can review material events such as clinical and scientific milestones, corporate presentations, patent developments, financing transactions and listing-related communications. Recent 8-K filings have furnished press releases on positive Phase 1 results for WP1066 in pediatric recurrent malignant brain tumors, updates on enrollment and unblinding plans for the pivotal MIRACLE Phase 2B/3 AML trial of Annamycin plus cytarabine (AnnAraC), and independent assessments of Annamycin’s cardiotoxicity profile. Other 8-Ks describe grant-funded and investigator-initiated research agreements for Annamycin in pancreatic cancer and glioblastoma multiforme, as well as patent grants for preliposomal Annamycin lyophilizates.
Moleculin’s filings also document capital markets and listing matters, including notices from Nasdaq regarding bid price and stockholders’ equity requirements, the company’s responses and appeal plans, and the implementation of a 1-for-25 reverse stock split with continued trading under the MBRX symbol. Additional filings cover warrant exercises, special stockholder meeting results and approvals related to equity issuances.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and are paired with AI-powered summaries that highlight key points, such as clinical trial status, regulatory designations, patent protections and financing terms. Users can quickly scan 8-Ks and related reports to understand how Moleculin is advancing Annamycin, WP1066 and WP1122, how it is managing its Nasdaq listing, and how corporate actions may affect shareholders. This page also helps surface insider and governance-related information when reported through the company’s SEC submissions.
Moleculin Biotech, Inc. reports that it has issued a press release announcing positive results from a physician-sponsored Phase 1 clinical trial conducted at Emory University. The trial took place at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta and was led by pediatric oncologist Tobey MacDonald, MD, who identified STAT3 as critical to certain childhood brain tumors and directs the Pediatric Neuro-Oncology Program.
The company has attached the press release as Exhibit 99.1 to this report and incorporated it by reference, while specifying that the information is being furnished under the securities laws rather than filed.
Moleculin Biotech, Inc. reports that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing of its common stock. The company had previously been notified on June 27, 2025 that its shares failed to meet the Nasdaq Listing Rule 5550(a)(2) requirement after trading below $1.00 per share for 30 consecutive business days.
Nasdaq’s Listing Qualifications Staff informed Moleculin on December 15, 2025 that the company is back in compliance because the closing bid price of its common stock was at or above $1.00 per share for 10 consecutive business days from December 1, 2025 through December 12, 2025. Nasdaq indicated that the company is now in compliance with the bid price rule and that the matter is closed.
Moleculin Biotech, Inc. (MBRX) furnished a new corporate presentation as an exhibit to a current report. The presentation, identified as Exhibit 99.1, is being used for the company’s corporate communications and is posted on its website. The company states that this material is being furnished under Regulation FD and will not be treated as "filed" for purposes of the Securities Exchange Act of 1934 or automatically incorporated into other SEC filings unless specifically referenced. This is primarily a disclosure and investor‑information update rather than an operational or financial event.
Moleculin Biotech, Inc. reported that Nasdaq has issued a determination to delist its common stock after the company failed to regain compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity or specified alternative criteria.
Nasdaq previously gave the company until November 19, 2025 to regain compliance, but a letter dated November 20, 2025 states that the company remains non-compliant.
Unless Moleculin requests a hearing before a Nasdaq panel by November 28, 2025, its securities are scheduled to be delisted on December 2, 2025. The company intends to appeal this determination under Nasdaq’s procedures, and its common stock is expected to continue trading on The Nasdaq Capital Market under the symbol “MBRX” while the appeal is pending.
Moleculin Biotech (MBRX) filed a Form 4 for EVP & CFO Jonathan P. Foster reporting equity awards dated 11/12/2025. The filing lists a stock option for 600,000 shares at an exercise price of $0.49, expiring 11/12/2035, vesting in four equal annual installments beginning on the first anniversary. It also reports 400,000 performance-based RSUs that vest in 20% increments upon achievement of specified clinical milestones; 100% vest upon a change of control as defined in the 2024 Stock Plan. Following these transactions, derivative securities beneficially owned were 2,017,695, held directly.
Moleculin Biotech (MBRX) disclosed insider equity awards to its CEO and President on 11/12/2025. The filing reports a stock option grant for 830,000 shares at an exercise price of $0.49, vesting in four equal annual installments beginning on the first anniversary of the grant, subject to continued service.
The CEO also received 750,000 performance-based restricted stock units, each representing one share. These RSUs vest in 20% increments upon achievement of specified clinical milestones, and 100% vest upon a change of control as defined in the 2024 Stock Plan. Following these awards, the form shows 3,960,731 derivative securities beneficially owned.
Moleculin Biotech (MBRX) reported a director’s stock option grant on a Form 4. The filing shows 150,000 stock options with an exercise price of $0.49, granted on 11/12/2025. These options vest on 11/12/2026, subject to continued Board service, and expire on 11/12/2035.
Following this transaction, the filing lists 164,001 derivative securities beneficially owned, held in direct ownership. The options were issued in connection with the reporting person’s Board of Director service.
Moleculin Biotech (MBRX) reported a director’s grant of 150,000 stock options (Transaction Code A) at an exercise price of $0.49 on November 12, 2025.
The options vest on November 12, 2026, subject to continued Board service, and expire on November 12, 2035. Following this grant, the reporting person beneficially owned 165,336 derivative securities, held directly. The filing notes the options were issued in connection with Board service.
Moleculin Biotech (MBRX) reported a director’s grant of stock options. The filing shows 150,000 stock options (right to buy) at an exercise price of $0.49 per share on 11/12/2025, coded “A” for award. These options vest on 11/12/2026 and expire on 11/12/2035, issued in connection with Board service. Following this transaction, the director beneficially owned 165,169 derivative securities, held directly.
Moleculin Biotech reported a wider quarterly loss and a new stockholders’ deficit. For Q3 2025, net loss was $25,399,000 as operating expenses fell to $5,906,000 but were overshadowed by a $20,609,000 loss on issuance of warrant liabilities. Year‑to‑date net loss reached $49,112,000.
Cash and cash equivalents were $6,703,000 as of September 30, 2025, up from $4,278,000 at year‑end, aided by warrant exercises and equity transactions. Total assets were $20,353,000. A new long‑term warrant liability of $41,333,000 and accumulated losses drove stockholders’ equity to a deficit of $26,920,000.
The company disclosed substantial doubt about its ability to continue as a going concern, noting current cash is not sufficient for at least one year. It received Nasdaq notices related to stockholders’ equity and bid price, with an extension to November 19, 2025 for equity compliance and a bid‑price compliance period until December 24, 2025. In 2025, Moleculin completed multiple financings, including a June offering with Series E warrants ($0.37 exercise price) and an August inducement generating $6.0 million and issuing Series F warrants ($0.55 exercise price). A July 2025 ATM program authorizes up to $6.5 million.